(0.39%) 5 119.90 points
(0.37%) 38 381 points
(0.51%) 16 009 points
(-1.41%) $82.67
(4.42%) $2.01
(0.44%) $2 357.60
(0.32%) $27.62
(4.45%) $963.15
(-0.25%) $0.932
(-0.39%) $10.98
(-0.57%) $0.796
(1.68%) $93.42
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 9.67%
Live Chart Being Loaded With Signals
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally...
Stats | |
---|---|
Dagens volum | 690 935 |
Gjennomsnittsvolum | 2.33M |
Markedsverdi | 4.82B |
EPS | $0 ( 2024-02-15 ) |
Neste inntjeningsdato | ( $0.970 ) 2024-05-02 |
Last Dividend | $0.280 ( 2023-11-10 ) |
Next Dividend | $0 ( N/A ) |
P/E | 4.72 |
ATR14 | $0.0100 (0.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-29 | Arjona Ferreira Juan Camilo | Buy | 108 932 | Stock Option (right to buy) |
2024-03-29 | Arjona Ferreira Juan Camilo | Buy | 26 595 | Restricted Stock Units |
2024-03-31 | Morrissey Joseph T. Jr. | Buy | 7 794 | Common Stock |
2024-03-31 | Morrissey Joseph T. Jr. | Sell | 2 328 | Common Stock |
2024-03-31 | Morrissey Joseph T. Jr. | Buy | 3 936 | Common Stock |
INSIDER POWER |
---|
64.91 |
Last 100 transactions |
Buy: 2 246 661 | Sell: 486 702 |
Volum Korrelasjon
Organon & Co. Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Organon & Co. Korrelasjon - Valuta/Råvare
Organon & Co. Økonomi
Annual | 2023 |
Omsetning: | $6.26B |
Bruttogevinst: | $3.75B (59.84 %) |
EPS: | $4.01 |
FY | 2023 |
Omsetning: | $6.26B |
Bruttogevinst: | $3.75B (59.84 %) |
EPS: | $4.01 |
FY | 2022 |
Omsetning: | $6.17B |
Bruttogevinst: | $3.88B (62.84 %) |
EPS: | $3.61 |
FY | 2021 |
Omsetning: | $6.30B |
Bruttogevinst: | $3.92B (62.21 %) |
EPS: | $5.33 |
Financial Reports:
No articles found.
Organon & Co. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.280 (N/A) |
$0.280 (N/A) |
$0.280 (N/A) |
$0.280 (N/A) |
$0.280 (N/A) |
$0.280 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.280 | 2021-08-20 |
Last Dividend | $0.280 | 2023-11-10 |
Next Dividend | $0 | N/A |
Payout Date | 2023-12-14 | |
Next Payout Date | N/A | |
# dividends | 10 | -- |
Total Paid Out | $2.80 | -- |
Avg. Dividend % Per Year | 2.08% | -- |
Score | 4.25 | -- |
Div. Sustainability Score | 7.83 | |
Div.Growth Potential Score | 4.25 | |
Div. Directional Score | 6.04 | -- |
Year | Amount | Yield |
---|---|---|
2021 | $0.560 | 1.68% |
2022 | $1.120 | 3.59% |
2023 | $1.120 | 3.99% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
ZTR | Dividend King | 2024-02-09 | Monthly | 37 | 8.35% | 8.50 |
ORC | Dividend Royal | 2023-11-29 | Monthly | 12 | 9.23% | 8.50 |
NCZ | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.79% | 8.50 |
KIO | Dividend Royal | 2023-12-14 | Monthly | 12 | 7.05% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
SJT | Dividend Royal | 2023-11-29 | Monthly | 39 | 12.52% | 8.50 |
GOF | Dividend Royal | 2023-11-14 | Monthly | 18 | 8.03% | 8.50 |
SRV | Dividend Royal | 2023-12-04 | Monthly | 18 | 7.53% | 8.50 |
VGI | Dividend Royal | 2024-02-09 | Monthly | 13 | 7.36% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.163 | 1.500 | 6.73 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0848 | 1.200 | 7.17 | 8.61 | [0 - 0.3] |
returnOnEquityTTM | -2.10 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0.287 | -1.000 | 7.13 | -7.13 | [0 - 1] |
currentRatioTTM | 1.545 | 0.800 | 7.28 | 5.82 | [1 - 3] |
quickRatioTTM | 0.835 | 0.800 | 9.79 | 7.83 | [0.8 - 2.5] |
cashRatioTTM | 0.237 | 1.500 | 9.79 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.726 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 1.221 | 1.000 | -0.659 | -0.659 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.13 | 2.00 | 8.96 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.10 | 2.00 | 8.95 | 10.00 | [0 - 20] |
debtEquityRatioTTM | -125.14 | -1.500 | -10.00 | 10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.598 | 1.000 | 3.36 | 3.36 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.103 | 1.000 | 9.94 | 9.94 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.0912 | 1.000 | -0.604 | -0.604 | [0.2 - 2] |
assetTurnoverTTM | 0.519 | 0.800 | 9.87 | 7.90 | [0.5 - 2] |
Total Score | 7.83 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 4.64 | 1.000 | 9.63 | 0 | [1 - 100] |
returnOnEquityTTM | -2.10 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.10 | 2.00 | 9.30 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 6.04 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.13 | 2.00 | 8.96 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.287 | 1.500 | 7.13 | -7.13 | [0 - 1] |
pegRatioTTM | -0.141 | 1.500 | -4.27 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.128 | 1.000 | 9.31 | 0 | [0.1 - 0.5] |
Total Score | 4.25 |
Organon & Co.
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.